Ï㽶ÊÓƵ

H. Evin Gulbahce
No Rating Available
(Learn About Our Rating System)

H. Evin Gulbahce, MD, MSCI

Languages spoken: English

  • Dr. Gulbahce is a professor of pathology at the Ï㽶ÊÓƵ of Utah School of Medicine. She received her MD from Hacettepe Ï㽶ÊÓƵ in Ankara, Turkey, and completed a residency in anatomic and clinical pathology and a surgical pathology fellowship at the Ï㽶ÊÓƵ of Minnesota. Her research interests include HER2 testing, and breast cancer risk factors, specifically risk factor for basal-like and triple negative cancers.

    Specialties

    • Pathology, Anatomical

  • Dr. Gulbahce is a professor of pathology at the Ï㽶ÊÓƵ of Utah School of Medicine. She received her MD from Hacettepe Ï㽶ÊÓƵ in Ankara, Turkey, and completed a residency in anatomic and clinical pathology and a surgical pathology fellowship at the Ï㽶ÊÓƵ of Minnesota. Her research interests include HER2 testing, and breast cancer risk factors, specifically risk factor for basal-like and triple negative cancers.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary

    Education history

    Graduate Training Clinical Investigation - Ï㽶ÊÓƵ of Utah M.S.C.I
    Fellowship Surgical Pathology - Ï㽶ÊÓƵ of Minnesota Fellow
    Residency Anatomic and Clinical Pathology - Ï㽶ÊÓƵ of Minnesota Resident
    Professional Medical Medicine - Hacettepe Ï㽶ÊÓƵ School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Wilcock D, Sirohi D, Albertson D, Cleary AS, Coleman JF, Jedrzkiewicz J, Mahlow J, Ruano AL, Gulbahce HE (2023). Clinicopathologic Features of Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0) Breast Cancers. Arch Pathol Lab Med. ()
    2. McMurtry V, Cleary AS, Ruano AL, Lomo L, Gulbahce HE (2023). Metaplastic Breast Carcinoma: Clinicopathologic Features and Recurrence Score Results From a Population-based Database. Am J Clin Oncol, 46(12), 559-566. ()
    3. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi D (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Arch Pathol Lab Med. ()
    4. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi D (2022). Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. Int J Surg Pathol, 30(7), 734-742. ()
    5. Wilcock DM, Sirohi D, Coleman JF, Gulbahce HE (2022). Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity. Hum Pathol, 126, 129-135. ()
    6. Jedrzkiewicz J, Sirohi D, Uvejzovic N, Gulbahce HE (2021). RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory. Mod Pathol, 35, 549-553. ()
    7. Gulbahce HE, Downs-Kelly E, Herget KA, Stoddard GJ (2021). The 21-Gene Recurrence Score in Special Histologic Subtypes of Breast Cancer: A Population-Based Study. Arch Pathol Lab Med, 146, 478-484. ()
    8. Mahlow J, Goold EA, Jedrzkiewicz J, Gulbahce HE (2020). What to Expect From the New ASCO/CAP Guideline Recommendations for Hormone Receptor Testing in Breast Cancer: A National Reference Laboratory Experience. Appl Immunohistochem Mol Morphol, 29(4), 245-250. ()
    9. Gulbahce HE, White S, Herget KA, Stoddard G, Camp NJ, Buys SS, Sweeney C (2020). 21-gene recurrence score testing utilization among older women from different races: A population-based study. J Geriatr Oncol, 12(2), 206-211. ()
    10. Lin L, Sirohi D, Coleman JF, Gulbahce HE (2019). American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. Am J Clin Pathol, 152(4), 479-485. ()
    11. Schneider F, Jin Y, Van Smaalen K, Gulbahce EH, Factor RE, Li X (2019). The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers. Am J Clin Pathol, 151(5), 504-510. ()
    12. Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, Sweeney C (2018). Differences in molecular features of triple-negative breast cancers based on the age at diagnosis. Cancer, 124(24), 4676-4684. ()
    13. Stewart RL, Caron JE, Gulbahce EH, Factor RE, Geiersbach KB, Downs-Kelly E (2017). HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol, 30(11), 1561-1566. ()
    14. Gulbahce HE (2017). Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory. Am J Clin Pathol, 148(4), 308-313. ()
    15. Gulbahce HE, Blair CK, Sweeney C, Salama ME (2016). Quantification of Estrogen Receptor Expression in Normal Breast Tissue in Postmenopausal Women With Breast Cancer and Association With Tumor Subtypes. Appl Immunohistochem Mol Morphol, 25(8), 548-552. ()
    16. Hui L, Geiersbach KB, Downs-Kelly E, Gulbahce HE (2016). RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory. Arch Pathol Lab Med, 141(2), 274-278. ()
    17. Johnson ED, Gulbahce E, McNally J, Buys SS (2016). Malignant Phyllodes Tumor Presenting in Bone, Brain, Lungs, and Lymph Nodes. Case Rep Oncol, 9(3), 861-868. ()
    18. Willmore-Payne C, Damjanovich-Colmenares K, Pasi AV, Werner TL, Gulbahce HE, Downs-Kelly E, Geiersbach KB (2016). Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. Am J Clin Pathol, 146(5), 618-626. ()
    19. Geiersbach KB, Willmore-Payne C, Pasi AV, Paxton CN, Werner TL, Xu X, Wittwer CT, Gulbahce HE, Downs-Kelly E (2016). Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. Am J Clin Pathol, 146(4), 439-47. ()
    20. Witt BL, Albertson DJ, Coppin MG, Horrocks CF, Post M, Gulbahce HE (2014). Use of in situ hybridization for HPV in head and neck tumors: experience from a national reference laboratory. Head Neck Pathol, 9(1), 60-4. ()
    21. Singh C, Manivel JC, Truskinovsky AM, Savik K, Amirouche S, Holler J, Thyagarajan B, Gulbahce HE, Pambuccian SE (2014). Variability of pathologists' utilization of p16 and ki-67 immunostaining in the diagnosis of cervical biopsies in routine pathology practice and its impact on the frequencies of cervical intraepithelial neoplasia diagnoses and cytohistologic correlations. Arch Pathol Lab Med, 138(1), 76-87. ()
    22. Gulbahce HE, Sweeney C, Surowiecka M, Knapp D, Varghese L, Blair CK (2013). Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors. Hum Pathol, 44(11), 2427-31. ()
    23. Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR (2010). Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone Marrow Transplant, 46(3), 368-71. ()
    24. Ward KA, Ecker PM, White RR, Melnik TE, Gulbahce EH, Wilke MS, Sangueza OP (2010). Papillary intralymphatic angioendothelioma of the thigh: A case report and review of the literature. Dermatol Online J, 16(4), 4. ()
    25. Beckman JD, Belcher JD, Vineyard JV, Chen C, Nguyen J, Nwaneri MO, OSullivan MG, Gulbahce E, Hebbel RP, Vercellotti GM (2009). Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. Am J Physiol Heart Circ Physiol, 297(4), H1243-53. ()
    26. Hart C, Opperman DA, Gulbahce E, Adams G (2005). Branchial cleft cyst: a rare diagnosis in a 91-year-old patient. Otolaryngol Head Neck Surg, 135(6), 955-7. ()
    27. Oktay MF, Cureoglu S, Schachern PA, Gulbahce E, Paparella MM, Hayasi H (2005). Histologic changes in the anterior mallear ligament and the head of the malleus in otosclerosis. Otolaryngol Head Neck Surg, 134(2), 232-5. ()
    28. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M (2004). Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology, 233(2), 424-31. ()
    29. Woodard JP, Gulbahce E, Shreve M, Steiner M, Peters C, Hite S, Ramsay NK, DeFor T, Baker KS (2000). Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone Marrow Transplant, 25(3), 293-300. ()

    Case Report

    1. Johnson ED, Downs-Kelly E, Bull DA, Gulbahce HE (2017). Primary Cystic Pleuropulmonary Synovial Sarcoma Presenting as Recurrent Pneumothorax. Case Rep Oncol, 10(2), 660-665. ()

    Letter

    1. Balatico M, Ruano AL, Cleary AS, Lomo L, Gulbahce HE (2023). Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based Database. (Letter to the Editor) [Letter to the editor]. Arch Pathol Lab Med, 148(3), 263-264. ()
    2. Gulbahce HE, Coleman JF, Sirohi D (2019). Interference of Tissue-Marking Dyes With Fluorescence In Situ Hybridization Assays. [Letter to the editor]. Arch Pathol Lab Med, 143(11), 1299. ()
    3. Gulbahce HE, Factor R, Geiersbach K, Downs-Kelly E (2016). HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer. [Letter to the editor]. Arch Pathol Lab Med, 140(8), 741. ()